MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319934 | Name: Prucalopride Succinate
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Prucalopride is a 5-HT4R agonist.

Chemical Structure

Prucalopride Succinate
Prucalopride Succinate
CAS#179474-85-2 (Succinate)

Theoretical Analysis

MedKoo Cat#: 319934

Name: Prucalopride Succinate

CAS#: 179474-85-2 (Succinate)

Chemical Formula: C22H32ClN3O7

Exact Mass: 0.0000

Molecular Weight: 485.96

Elemental Analysis: C, 54.38; H, 6.64; Cl, 7.29; N, 8.65; O, 23.05

Price and Availability

Size Price Availability Quantity
100mg USD 250.00 2 Weeks
200mg USD 350.00 2 Weeks
500mg USD 550.00 2 Weeks
1g USD 950.00 2 Weeks
2g USD 1,450.00 2 Weeks
5g USD 2,250.00 2 Weeks
10g USD 3,950.00 2 Weeks
20g USD 5,450.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
179474-85-2 (Succinate) 179474-81-8 (free base) 179474-80-7 (HCl)
Synonym
R-108512; R 108512; R108512; R 093877; R-093877; R093877; R 93877; R-93877; R93877; Prucalopride Succinate; Resolor; Resotran; Motegrity;
IUPAC/Chemical Name
4-amino-5-chloro-N-(1-(3-methoxypropyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide succinate
InChi Key
QZRSNVSQLGRAID-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H26ClN3O3.C4H6O4/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14;5-3(6)1-2-4(7)8/h11-12H,2-10,20H2,1H3,(H,21,23);1-2H2,(H,5,6)(H,7,8)
SMILES Code
O=C(O)CCC(O)=O.O=C(C1=C(OCC2)C2=C(N)C(Cl)=C1)NC3CCN(CCCOC)CC3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 485.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Derayea SM, Mohammed FF, Badr El-Din KM. Sensitive spectrofluorimetric determination of the prokinetic drug prucalopride succinate based on supramolecular aggregation approach with evaluation of method greenness: application to content uniformity test. Luminescence. 2023 Dec;38(12):2065-2072. doi: 10.1002/bio.4597. Epub 2023 Oct 10. PMID: 37740522. 2: Nour IM, Mohamed AR, Hasan MA, Badrawy M. Eco-friendly-assessed micellar- fluorimetric platform for concurrent analysis of empagliflozin and prucalopride succinate in biological fluids: Docking simulation. Spectrochim Acta A Mol Biomol Spectrosc. 2023 Aug 5;296:122715. doi: 10.1016/j.saa.2023.122715. Epub 2023 Apr 5. PMID: 37031481. 3: Jiang LF, Wu J, Fu Q, Jiang LH, Chen C, Zhu D, Zhong YM. [Clinical observation of acupuncture at Huiyin (CV 1) for chronic severe functional constipation]. Zhongguo Zhen Jiu. 2023 Feb 12;43(2):128-32. Chinese. doi: 10.13703/j.0255-2930.20220314-k0001. PMID: 36808504. 4: Saad MT, Zaazaa HE, Fattah TA, Boltia SA. Bioanalytical Validated Spectrofluorimetric Method for the Determination of Prucalopride succinate in Human Urine Samples and Its Greenness Evaluation. J Fluoresc. 2023 Jul;33(4):1609-1617. doi: 10.1007/s10895-023-03150-1. Epub 2023 Feb 17. PMID: 36800042; PMCID: PMC10361904. 5: Elshahed MS, Toubar SS, Ashour AA, El-Eryan RT. Novel sensing probe using Terbium-sensitized luminescence and 8-hydroxyquinoline for determination of prucalopride succinate: green assessment with Complex-GAPI and analytical Eco- Scale. BMC Chem. 2022 Oct 21;16(1):80. doi: 10.1186/s13065-022-00876-0. PMID: 36271435; PMCID: PMC9587542. 6: Liu G, Hrabe J, Sanchez R. Colostomy as a definitive treatment in an ALS patient with acute colonic Pseudo-obstruction refractory to medical management, a case report. BMC Neurol. 2022 Sep 22;22(1):366. doi: 10.1186/s12883-022-02893-x. PMID: 36138349; PMCID: PMC9494822. 7: Hussar DA, Kludjian GA. Prucalopride succinate, Fostamatinib disodium hexahydrate, Avatrombopag maleate, and Lusutrombopag. J Am Pharm Assoc (2003). 2019 Jul-Aug;59(4):601-604. doi: 10.1016/j.japh.2019.05.013. PMID: 31296323. 8: Flach S, Scarfe G, Dragone J, Ding J, Seymour M, Pennick M, Pankratz T, Troy S, Getsy J. A Phase I Study to Investigate the Absorption, Pharmacokinetics, and Excretion of [(14)C]Prucalopride After a Single Oral Dose in Healthy Volunteers. Clin Ther. 2016 Sep;38(9):2106-15. doi: 10.1016/j.clinthera.2016.08.003. Epub 2016 Sep 7. PMID: 27614912. 9: Chen H, Hong F, Chen Y, Li J, Yao YS, Zhang Y, Zheng LF, Zhu JX. Activation of islet 5-HT4 receptor regulates glycemic control through promoting insulin secretion. Eur J Pharmacol. 2016 Oct 15;789:354-361. doi: 10.1016/j.ejphar.2016.07.024. Epub 2016 Jul 14. PMID: 27423314. 10: Mahamuni BS, Jajula A, Awasthi A, Kalariya PD, Talluri MV. Selective separation and characterisation of stress degradation products and process impurities of prucalopride succinate by LC-QTOF-MS/MS. J Pharm Biomed Anal. 2016 Jun 5;125:219-28. doi: 10.1016/j.jpba.2016.03.047. Epub 2016 Mar 24. PMID: 27037978. 11: Bassotti G, Gambaccini D, Bellini M. Prucalopride succinate for the treatment of constipation: an update. Expert Rev Gastroenterol Hepatol. 2016;10(3):291-300. doi: 10.1586/17474124.2016.1129897. Epub 2016 Jan 29. PMID: 26647167. 12: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Nov;32(9):675-703. doi: 10.1358/mf.2010.32.9.1563109. PMID: 21225019. 13: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Apr;31(3):183-226. PMID: 19536362. 14: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Oct;30(8):643-72. PMID: 19088949. 15: Tomillero A, Moral MA. Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95. PMID: 18850047. 16: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Oct;25(8):653-82. PMID: 14671684.